Company intelligence / Profile preview
Cellion BioMed
Seongnam-si, Gyeonggi-do, South Koreacellionbiomed.com ↗
- Ownership
- Private
- Development stage
- Other
01
Overview
Cellion BioMed is a South Korean biotechnology company dedicated to developing first-in-class therapeutics for refractory diseases, with a primary focus on fibrosis and inflammatory conditions. The company utilizes its proprietary platform to identify and optimize small molecule candidates that modulate key signaling pathways, such as TGF-β and S1P. Its lead program, CB-101, is being developed for the treatment of idiopathic pulmonary fibrosis (IPF) and nonalcoholic steatohepatitis (NASH). Cellion BioMed aims to address significant unmet medical needs in the global healthcare market through innovative drug discovery and strategic clinical development.
- Therapeutic areas
- OncologyPulmonologyDermatologyGastroenterology
- Modalities
- Small molecule
- Industry
- Biotech
02
Drug pipeline
5 assets4 more assets in the full pipeline.
Beyond the preview
Go deeper on Cellion BioMed.
Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.
Clinical trials
Follow clinical development from trial design and recruitment through results.
- Trial phase
- Status
- Readouts
Licensing & deals
Explore licensing agreements, acquisitions, and the assets behind each deal.
- Partners
- Deal terms
- Milestones
Funding history
Trace financing activity and the investors behind a company’s development.
- Funding rounds
- Investors
- Capital raised
Competitive landscape
Compare peer pipelines by target, modality, and therapeutic area.
- Peer companies
- Targets
- Pipeline overlap
Technologies & patents
Explore technology platforms and the patent landscape around relevant assets.
- Platforms
- Patents
- Assignees
Research & analysis
Connect company news and source material to the questions you’re investigating.
- Company news
- Sources
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on Cellion BioMed.